Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MP-470 + docetaxel
- Development stage
- Preclinical
- Lead developer
- SuperGen
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
MP-470 + docetaxel is a combination therapy under investigation primarily for cancer treatment, especially in prostate cancer models. MP-470 is a novel small molecule receptor tyrosine kinase inhibitor that targets multiple kinases, including AXL and members of the HER family (EGFR/HER1, HER2/neu, and HER3), thereby inhibiting downstream PI3K/Akt signaling pathways involved in tumor growth and survival[6][3]. Docetaxel is an antineoplastic agent classified as a taxane derivative; it binds to tubulin in microtubules, promoting their assembly while inhibiting disassembly. This stabilization disrupts mitosis and leads to cell death[8][5]. The combination has shown enhanced efficacy over either agent alone by more effectively suppressing AXL expression and overcoming resistance mechanisms in preclinical prostate cancer models[3].
- Brand names
- TaxotereDocefrez
- Other names
- RP56976RP-56976RP 56976
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)TUBB (Tubulin (alpha and beta subunits))FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on MP-470 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MP-470 + docetaxel.